New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of injection drugs and pharmaceutical products in the People’s Republic of China. The company’s pharmaceutical products include injections, capsules, tablets, and other drugs for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, parenteral nutrition, hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor relating hepatitis B and chronic hepatitis C, respiratory tract infections, urinary tract infections, genitourinary system infections, intra-abdominal infections, bone and joint infections, septicemia, catabolism, hypermetabolism, pneumonia, skin and soft tissue infections, pelvic inflammatory, diarrhea and digestive system relevant illness, biliary tract infection, and other infections. It also offers marketing and promotion services of drugs. The company was founded in 2001 and is headquartered in Hangzhou, the People’s Republic of China.